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Summary
G protein-coupled receptors (GPCRs) are the largest family
of signaling proteins expressed in every cell in the body
and are targeted by the majority of clinically used drugs [1].
GPCR signaling, including rhodopsin-driven phototransduc-
tion, is terminated by receptor phosphorylation followed by
arrestin binding [2]. Genetic defects in receptor phosphoryla-
tion and excessive signaling by overactive GPCR mutants
result in a wide variety of diseases, from retinal degeneration
to cancer [3–6]. Here, we tested whether arrestin1 mutants
with enhanced ability to bind active unphosphorylated
rhodopsin [7–10] can suppress uncontrolled signaling, by-
passing receptor phosphorylation by rhodopsin kinase
(RK) and replacing this two-step mechanism with a single-
step deactivation in rod photoreceptors. We show that in
this precisely timed signaling system with single-photon
sensitivity [11], an enhanced arrestin1 mutant partially
compensates for defects in rhodopsin phosphorylation,
promoting photoreceptor survival, improving functional
performance, and facilitating photoresponse recovery.
These proof-of-principle experiments demonstrate the feasi-
bility of functional compensation in vivo for the first time,
which is a promising approach for correcting genetic defects
associated with gain-of-function mutations. Successful
modification of protein-protein interactions by appropriate
mutations paves the way to targeted redesign of signaling
pathways to achieve desired functional outcomes.
Results and Discussion
Enhanced Arrestin1 Mutant Protects Photoreceptors
in the Absence of Rhodopsin Phosphorylation
Wild-type (WT) arrestins bind active unphosphorylated G
protein-coupled receptors (GPCRs) with low affinity [2]. The
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cantly increases arrestin1 binding to unphosphorylated light-
activated rhodopsin (Rh*) in vitro [7, 12]. To test whether
enhanced mutants can compensate for the defects of
rhodopsin phosphorylation in vivo, we generated transgenic
mice expressing mouse arrestin1 (Arr1) with triple alanine
substitution in the C tail (3A) that demonstrates high binding
to Rh* (see Figure S1 available online). Transgenic lines with
high (3A-240) and moderate (3A-50) expression, correspond-
ing to 240% and 50% of endogenous Arr1 in WT mice, respec-
tively (Table S1), were bred onto Arr1 knockout (3A-50arr12/2
and 3A-240arr12/2) and RK and Arr1 double-knockout
(3A-240arr12/2rk2/2 and 3A-50arr12/2rk2/2) backgrounds.
Photoreceptors in rk2/2 and arr12/2 mice reared in cyclic
light are disorganized and eventually degenerate [13, 14].
Dark rearing preserves normal retinal morphology, suggesting
that excessive rhodopsin signaling in these animals damages
photoreceptors. To test whether the mutant arrestin prevents
light damage, mice for morphological and electrophysiological
studies were raised in cyclic light. We measured two morpho-
logical parameters: the length of the rod outer segments (OS),
as a measure of overall photoreceptor health, and the thick-
ness of the outer nuclear layer (ONL), which reflects the
number of surviving rods (Figure 1; Figure S2).
Healthy OS in WT mice maintain organized structure with
lengths ofw20 mm in peripheral retina to 28 mm in the central
retina (Figure 1A). The OS length progressively decreased in
mice lacking arrestin, RK, or both (Figure 1; Table 1). The
expression of mutant arrestin on the arr12/2 background
significantly increased the OS length, although not to WT level
(Figure 1B). The OS of rk2/2 and arr12/2rk2/2 animals were
similar, indicating that WT arrestin has no beneficial effect in
the absence of RK (Figure 1C). In contrast, 3A-240arr12/2rk2/2
and 3A-50arr12/2rk2/2 mice expressing mutant arrestin had
significantly longer OS than rk2/2 or arr12/2rk2/2 animals
(Figure 1C). The morphological protection afforded by the
mutant was more evident at 16 weeks than at 8 weeks, indi-
cating that 3A arrestin slowed down progressive loss of OS
in RK-deficient mice.
Photoreceptor degeneration inarr12/2animals was reflected
in progressive thinning of the ONL with age (Table 1;
Figure S2A). The effect of the mutant on thearr12/2background
depended on its expression level. Moderate expression (3A-
50arr12/2) prevented photoreceptor loss, whereas high expres-
sion (3A-240arr12/2) yielded significantly thinner ONL than other
genotypes expressing RK (Figure S2A) (see Supplemental
Discussion). All RK-deficient groups had significantly thinner
ONL than WT animals (p < 0.0001). Enhanced arrestin improved
photoreceptor survival as compared to in rk2/2 mice in
3A-240arr12/2rk2/2 and 3A-50arr12/2rk2/2 lines across ages
and retinal subdivisions (Table 1), indicating that in the absence
of rhodopsin phosphorylation, enhanced arrestin protects
photoreceptors better than WT Arr1 (Figure S2B).
Thus, in animals with normal rhodopsin phosphorylation,
WT Arr1 affords healthier retinal morphology than the mutant.
In contrast, in RK-deficient mice, WT Arr1 does not protect
photoreceptors, whereas enhanced mutant significantly
improves their health and survival.
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by Enhanced Arrestin1 Mutant
To compare the ability of WT arrestin and 3A mutant to inacti-
vate rhodopsin, we used suction electrodes [11] to record
light-induced changes in membrane current in individual intact
rods. Flash responses of rk2/2 or arr12/2 rods are abnormally
prolonged [13–15]. Responses to flashes of varying strengths,
as well as the amplitude of the single-photon response, light
Figure 1. Phosphorylation-Independent Arrestin Protects Rod Outer Segments in the Absence of Rhodopsin Phosphorylation
(A) Combined differential interference contrast and green fluorescent Nissl images of retina sections of 8-week-old mice of the indicated genotypes,
enlarged to show the outer segment (OS) more clearly. The positions of the OS, inner segment (IS), and outer nuclear layer (ONL) are shown at the left.
(B and C) OS lengths measured in the central, middle, and peripheral retina were the average of inferior and superior hemispheres. Means6 SEM from three
animals per genotype are shown. OS length was compared separately for each age and retinal subdivision by one-way ANOVA with genotype as main factor,
followed by Scheffe’s post hoc test.
(B) *p < 0.05, **p < 0.01, ***p < 0.001 compared to wild-type (WT); ap < 0.05 compared to arr12/2. At 8 weeks in the central retina, OS in both transgenic strains
were significantly shorter than in WT mice (p = 0.0035 and p = 0.0008, respectively), but in 3A-50arr12/2mice, OS were significantly longer than in arr12/2mice
(p = 0.037). In the middle retina, ** applies to both transgenic lines; in the peripheral retina, *** applies to both transgenic and arr12/2 lines. At 16 weeks in the
central retina, OS in both transgenic strains were significantly shorter than in WT mice (p = 0.0014 and 0.0015) but longer than in arr12/2mice (p = 0.0213 and
0.0174, respectively for 3A-50arr12/2 and 3A-240arr12/2 lines). In the middle retina, *** applies to both transgenic lines; in the peripheral retina, *** applies to
both transgenic and arr12/2 lines.
(C) *p < 0.05, **p < 0.01, ***p < 0.001 compared to both arr1+/+rk2/2 and arr12/2rk2/2. bp < 0.05; bbp < 0.01 compared to arr1+/+rk2/2. There were no significant
differences in OS length between rk2/2 and arr12/2rk2/2 mice in any retinal subdivision at either age. High and moderate transgene expression similarly
increased the length of the OS, as evidenced by the absence of significant differences between 3A-50arr12/2rk2/2 and 3A-240arr12/2rk2/2 lines across retinal
subdivisions at both ages.
Table 1. Morphological and Functional Characteristics of Mice Expressing WT Arrestin1 and Enhanced Mutant in the Presence and Absence of Rhodopsin
Kinase
Retinal Morphology ERG Parameters
Mouse Line OS Length ONL Thickness Scotopic bmax (mV)
Scotopic b Wave I1/2
(log cd 3 s/m2)
Time of Half-Recovery
(thalf) (ms)
WT +++ +++ 370 6 38 22.810 6 0.044 378.8 6 29.8
arr1+/2 ++a +++ 407 6 73 23.223 6 0.078h 423.9 6 16.1
arr12/2 -aa +d ND ND ND
3A-240arr12/2 +aa,bb 2dd,f 384 6 82 22.522 6 0.217 333.7 6 13.9
3A-50arr12/2 +aa,b +dd,e 518 6 15 22.656 6 0.093 372.2 6 23.3
rk2/2 -aa 2dd 105 6 18 22.378 6 0.200 18670.2 6 3238.9
arr12/2rk2/2 -aa -dd,gg ND ND ND
3A-240arr12/2rk2/2 +aa,c +dd,g 110 6 21 22.478 6 0.026 10200.4 6 845.7j
3A-50arr12/2rk2/2 +aa,c +dd,g 102 6 3 23.015 6 0.161i 6571.6 6 730.7jj
Morphological data were statistically analyzed by repeated-measure ANOVA with retinal subdivision as a repeated measure and with genotype and age as
between-group factors separately for arr12/2 and rk2/2 backgrounds. OS, outer segments, ONL, outer nuclear layer. Because each morphological param-
eter is described by six measurements, here we have qualitatively characterized them by symbols, as follows: +++, very healthy; ++, healthy; +, relatively
healthy; -, unhealthy;2, very unhealthy. Means6 SD from 3–4 animals per genotype are shown. Statistical significance was obtained by Scheffe’s post hoc
comparison of means for genotype across ages and retinal subdivisions. OS shorter than WT: ap < 0.01, aap < 0.0001; OS longer than arr12/2: bp < 0.05,
bbp < 0.01; OS longer than rk2/2: cp < 0.001. There were no significant differences in the effects of the mutant on OS at the two expression levels on
the arr12/2 (p = 0.87) or rk2/2 (p = 0.38) background. ONL thinner than WT: dp < 0.01, ddp < 0.0001; ONL thicker than arr12/2: ep < 0.05; ONL thinner
than arr12/2: fp < 0.05; ONL thicker than rk2/2: gp < 0.01; ggp < 0.0001. Light sensitivity (flash intensity necessary to elicit half-maximum rod-driven
b-wave, I1/2) was analyzed by ANOVA with genotype as main factor (F(6,13)-4.547; p = 0.0106), followed by Scheffe’s post hoc test with correction for
multiple comparisons: hlight sensitivity higher (I1/2 lower) than 3A-240
arr12/2 (p = 0.0287); ilight sensitivity higher than rk2/2 (p = 0.0294). Time of half-recovery
of a-wave amplitude (thalf) shorter than in rk
2/2: jp = 0.0424; jjp < 0.0063.
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(A) Single-photon responses of individual rods from WT (n = 13), 3A-240arr12/2 (n = 19), and 3A-50arr12/2 (n = 9) rods. The arr12/2 trace shown for comparison
(n = 9) is from [33]. The parameters of these responses are reported in Table S2.
(B) Representative electroretinography (ERG) traces of WT, rk2/2, and 3A-50arr12/2rk2/2 mice.
(C) Comparison of mouse lines expressing enhanced arrestin on the arr12/2rk2/2 background. Means 6 SD for three animals per genotype are shown.
ERG responses of 3A-50arr12/2rk2/2 mice at a given flash strength were significantly greater than those of rk2/2 mice (p = 0.0017), although they did not
reach WT level (p = 0.0002).sensitivity, and time constant of recovery of 3A-50arr12/2,
3A-240arr12/2, and WT rods, were very similar (Figure 2A;
Figure S3A; Table S2).
Moderately bright flash responses of 3A-240arr12/2rk2/2
rods were indistinguishable from those of rk2/2 rods but re-
mained significantly slower than WT responses (Figure S3B).
Dim flashes produced long-lasting step-like responses of vari-
able durations in RK-deficient rods, reflecting the stochastic
decay of individual Rh* molecules [13, 16–18]. The distribu-
tions of response durations fit single (t = 3.2 s for rk2/2) or
double (t1 = 4.1 s, t2 = 24.3 s for arr1
2/2rk2/2) exponential
functions, the time constants of which reflect the average life-
time of Rh* molecules [13, 16]. In RK-deficient rods, expres-
sion of the arrestin mutant did not alter the appearance of
these step-like responses (Figure S4A). However, the distribu-
tion of response durations in 3A-240arr12/2rk2/2 rods lacked
the second, slow time constant observed in arr12/2rk2/2
rods (Figure S4B), indicating that the mutant could quench
the longer-lived fraction of Rh*. The time constant of the 3A-
240arr12/2rk2/2 distribution (t = 3.5 s) was similar to that of
the rk2/2 photoreceptors expressing WT arrestin1, and
average single-photon responses were indistinguishable
(Figure S4C). Thus, in an ex vivo single-cell paradigm, WT
and mutant arrestin1 appear to inactivate Rh* similarly. There-
fore, to elucidate functional differences underlying the
stronger protective effect of the mutant in RK-deficient rods
(Figure 1; Figure S2), we used electroretinography (ERG).
ERG is a noninvasive technique that allows quantitative char-
acterization of the function of the whole retina in live animals.
The early negative a-wave and subsequent positive b-wave
(Figure 2B) reflect light-induced suppression of the circulatingcurrent in photoreceptors and the response of downstream
cells to photoreceptor activation, respectively [19–21].
We compared mice with normal rhodopsin phosphorylation
expressing WT and mutant arrestin1 by recording responses
to a series of flashes and plotting the a- and b-wave amplitudes
as a function of flash intensity (Figure S5). Compared to WT,
light responses of arr12/2 mice are much smaller and detect-
able only at higher light levels, reflecting the contribution from
cone photoreceptors [22]. 3A-50arr12/2 mice showed WT-like
responses. The high-expression line (3A-240arr12/2) had lower
a- and b-wave amplitudes, consistent with the decreased
number of photoreceptors (Figure S2). However, maximum
rod-driven b-wave (bmax) and light sensitivity (flash intensity
producing half-maximum rod b-wave, I1/2) in both lines were
similar and did not differ from WT (Table 1). The rate of photo-
receptor recovery in vivo is determined in the double-flash
paradigm [23], where the first flash desensitizes photorecep-
tors and the amplitude of the response to the second flash is
plotted as a function of time interval between flashes. It is char-
acterized by halftime of recovery (thalf) [19]. The recovery
kinetics of both 3A-50arr12/2 and 3A-240arr12/2 mice were
indistinguishable from that of WT and arr1+/2 mice (Figures
3A and 3C), further confirming that the mutant successfully
takes over the functions of missing WT Arr1.
To directly compare the ability of WT and mutant arrestin to
‘‘turn off’’ unphosphorylated rhodopsin, we performed similar
experiments with rk2/2 mice and lines expressing enhanced
mutant on the arr12/2rk2/2 background. 3A-50arr12/2rk2/2 mice
had significantly greater b-wave amplitude than rk2/2 mice
(p = 0.0148), whereas 3A-240arr12/2rk2/2 mice were similar to
rk2/2 mice in this respect (Figure 2C). The light sensitivity of
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(A and B) The intensities of the first (desensitizing) and second (probe) flash were 0.4 and 0.65 log cd3 s/m2, respectively. The normalized amplitude of the
probe flash a-wave was plotted as a function of time elapsed after the first flash. The interval between two flashes was varied from 200 to 1,500 ms for mice
expressing RK (A) and from 800 to 90,000 ms for lines on the rk2/2 background (B).
(C and D) To calculate the time of half-recovery, recovery kinetics were fitted by polynomial nonlinear regression, with R2 > 0.95, as described in Supple-
mental Experimental Procedures. Means6 SD are shown in (A)–(D) (n = 4 for each genotype). The data were analyzed by one-way ANOVA with genotype as
a main factor, which was highly significant (F(6,21) = 29.938; p < 0.0001).
(C) The rates of recovery of 3A-240arr12/2 and 3A-50arr12/2 animals were not different from WT (p = 0.9796 and p = 0.9962, respectively).
(D) Both transgenic lines on the arr12/2rk2/2 background recovered significantly faster than rk2/2 (p = 0.0424 for 3A-240arr12/2rk2/2; p = 0.0063 for
3A-50arr12/2rk2/2).
(E) Representative ERG traces of the response to the second (test) flash of WT, RK2/2, and 3A-50arr12/2rk2/2 mice after indicated time intervals.3A-50arr12/2rk2/2 mice was comparable to that of WT animals
and higher than that of rk2/2mice (p = 0.0294). Most importantly,
in RK-deficient animals, the enhanced mutant ensured signifi-
cantly faster recovery from bright flashes than WT arrestin1 (Fig-
ures 3B, 3D, and 3E). The halftime of recovery wasw19 s in rk2/2
animals, but onlyw10 s in 3A-240arr12/2rk2/2 mice andw6 s in
3A-50arr12/2rk2/2 mice (Table 1). Thus, the enhanced mutant
has a superior ability to deactivate unphosphorylated rhodopsin
compared to WT arrestin, yielding faster photoresponse
recovery in phosphorylation-deficient photoreceptors in vivo.
Biological Implications of Functional Compensation
In Vivo
Both rhodopsin phosphorylation and Arr1 binding are neces-
sary for the timely shutoff of the photoresponse [13, 14, 16,
24]. Due to rapid dissociation of the complex, the affinity of
WT Arr1 for Rh* is low [25], but it can be significantly increased
by ‘‘activating’’ mutations [7, 12, 25]. WT arrestin1 does not
protect RK-deficient photoreceptors, whereas enhanced
mutant improves their morphology and survival. ERG analysis
revealed significant functional rescue afforded by enhanced
arrestin1 mutant: rods in 3A-50arr12/2rk2/2 mice showed
more robust responses and normal light sensitivity and recov-
ered three times faster than rk2/2 animals (Table 1). These
differences were not observed in single-cell recordings assay-
ing the activity of individual Rh* molecules, suggesting either
that the protective effect of the mutant Arr1 is revealed only
at higher flash intensities used in ERG or that it requires the
native photoreceptor environment. Our data indicate that the
enhanced mutant outperforms WT arrestin1 in quenching un-
phosphorylated rhodopsin in vivo. Clear correlation between
the functional rescue and morphological protection afforded
by the mutant (Table 1) supports the idea that excessiverhodopsin signaling in the absence of phosphorylation drives
photoreceptor demise in rk2/2 mice [13].
Based on our understanding of the inner workings of the
arrestin molecule, we designed an enhanced mutant that
compensates for the defects in receptor phosphorylation.
However, engineered single-step receptor inactivation yielded
slower recovery than the normal two-step mechanism. The
most likely reason for the partial rescue is that the complex
of the mutant with Rh* is not as stable as the Arr1-P-Rh*
complex. To construct an enhanced mutant that retains high
affinity for P-Rh*, we relieved a conformational constraint
(Figure S1). The extensive receptor-binding surface of Arr1
[26, 27] carries eight positively charged residues [10, 12, 28,
29] that bind three or more phosphates on P-Rh* [16, 30].
Unphosphorylated rhodopsin cannot neutralize these
charges, which may destabilize the arrestin-Rh* complex.
The replacement of positive charges with neutral hydrophilic
residues may improve the mutant’s performance. This
approach must be tested experimentally, although it has
an obvious downside: an improved mutant could become
selective for the Rh*, losing affinity for P-Rh* due to loss of
the phosphate-binding residues.
Defects in rhodopsin shutoff underlie several visual disor-
ders. Patients lacking RK or arrestin suffer from Oguchi
disease, a form of stationary night blindness [31, 32]. In these
loss-of-function cases, replacement of the missing protein is
the most straightforward strategy for gene therapy. Unfortu-
nately, when gain-of-function mutations underlie the
pathology (e.g., rhodopsin lacking phosphorylation sites in
retinitis pigmentosa [3–5]), WT proteins cannot solve the
problem. Theoretically, mutant mRNA can be eliminated by
an appropriately designed ribozyme. However, this approach
is hardly practical: it would require unrealistic 100% efficiency
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ylation-deficient rhodopsin is harmful [24]) without affecting
‘‘good’’ mRNA, which may differ by as little as one base. The
introduction of an enhanced arrestin to quench the signaling
of the overactive receptor is a logical alternative. Our data
demonstrate that this compensational approach yields partial
rescue in the most efficient GPCR-driven signaling system, rod
phototransduction. Its high amplification yields unparalleled
sensitivity, which makes photoreceptors particularly vulner-
able: rods are the only cell type in which the defects in GPCR
shutoff result in cell death. Increased survival and improved
functional performance of RK-deficient photoreceptors
expressing enhanced arrestin1 are two sides of the same
coin, independently demonstrating the compensational
potential of the mutant. Partial rescue in the exceptionally
demanding visual system suggests that a similar approach
would rein in excessive signaling by nonvisual GPCRs in other
cell types more efficiently.
Our results show that redesigning GPCR inactivation
machinery in living animals is feasible. This approach paves
the way for the development of compensational gene therapy
for congenital disorders associated with gain-of-function
mutations.
Supplemental Data
The Supplemental Data include Supplemental Results, Supplemental
Discussion, Supplemental Experimental Procedures, two tables, and six
figures and can be found with this article online at http://www.
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